SCI Pharmtech, Inc.

TWSE:4119 Stock Report

Market Cap: NT$5.3b

SCI Pharmtech Management

Management criteria checks 3/4

SCI Pharmtech's CEO is Wen-Chih Chou, appointed in Jun 2022, has a tenure of 4.08 years. directly owns 0.18% of the company’s shares, worth NT$9.39M. The average tenure of the management team and the board of directors is 4.1 years and 11.1 years respectively.

Key information

Wen-Chih Chou

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure4.1yrs
CEO ownership0.2%
Management average tenure4.1yrs
Board average tenure11.1yrs

Recent management updates

Recent updates

Analysis Article • Nov 17

Shareholders Shouldn’t Be Too Comfortable With SCI Pharmtech's (TWSE:4119) Strong Earnings

We didn't see SCI Pharmtech, Inc.'s ( TWSE:4119 ) stock surge when it reported robust earnings recently. We decided to...
Analysis Article • Mar 27

We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings

Shareholders didn't appear too concerned by SCI Pharmtech, Inc.'s ( TWSE:4119 ) weak earnings. We did some analysis and...
Analysis Article • Apr 07

Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates

SCI Pharmtech, Inc. ( TPE:4119 ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article • Mar 30

There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings

The market for SCI Pharmtech, Inc.'s ( TPE:4119 ) shares didn't move much after it posted weak earnings recently. Our...
Analysis Article • Mar 08

SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?

Today we'll take a closer look at SCI Pharmtech, Inc. ( TPE:4119 ) from a dividend investor's perspective. Owning a...
Analysis Article • Jan 25

SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years

SCI Pharmtech, Inc. ( TPE:4119 ) shareholders might be concerned after seeing the share price drop 21% in the last...
Analysis Article • Dec 30

Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates

Market forces rained on the parade of SCI Pharmtech, Inc. ( TPE:4119 ) shareholders today, when the analysts downgraded...
Analysis Article • Dec 29

Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?

SCI Pharmtech (TPE:4119) has had a rough month with its share price down 36%. But if you pay close attention, you might...
Analysis Article • Dec 08

Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?

Is SCI Pharmtech, Inc. ( TPE:4119 ) a good dividend stock? How can we tell? Dividend paying companies with growing...
Analysis Article • Nov 17

A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)

In this article we are going to estimate the intrinsic value of SCI Pharmtech, Inc. (TPE:4119) by taking the expected...

CEO Compensation Analysis

How has Wen-Chih Chou's remuneration changed compared to SCI Pharmtech's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

NT$96m

Dec 31 2025n/an/a

NT$107m

Sep 30 2025n/an/a

NT$115m

Jun 30 2025n/an/a

NT$482m

Mar 31 2025n/an/a

NT$522m

Dec 31 2024n/an/a

NT$535m

Sep 30 2024n/an/a

NT$484m

Jun 30 2024n/an/a

NT$138m

Mar 31 2024n/an/a

NT$276m

Dec 31 2023NT$6mNT$3m

NT$295m

Sep 30 2023n/an/a

NT$377m

Jun 30 2023n/an/a

NT$390m

Mar 31 2023n/an/a

NT$331m

Dec 31 2022NT$6mNT$4m

NT$309m

Sep 30 2022n/an/a

NT$210m

Jun 30 2022n/an/a

NT$192m

Mar 31 2022n/an/a

NT$55m

Dec 31 2021NT$3mNT$2m

NT$56m

Compensation vs Market: Insufficient data to establish whether Wen-Chih's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Wen-Chih's compensation has been consistent with company performance over the past year.

CEO

Wen-Chih Chou

4.1yrs
Tenure
NT$6,374,842
Compensation

Mr. Wen-Chih Chou serves as Director & GM at SCI Pharmtech, Inc. since December 17, 2001 and also serves as it's President from July 2022 and was its Plant Manager since September 01, 2009 until July 2022....

Leadership Team

NamePositionTenureCompensationOwnership
Wen-Chih Chou
President4.1yrsNT$6.37m0.18%
NT$ 9.4m
Deiter Yang
Accounting Supervisor23.5yrsNT$3.67mno data
Wei-Song Yin
Assistant Vice President of Operating Div.3yrsno datano data
Ricky Liu
Sustainable Environment Team Manager & PDM/EH Managerno datano datano data
4.1yrs
Average Tenure

Experienced Management: 4119's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wen-Chih Chou
President24.6yrsNT$6.37m0.18%
NT$ 9.4m
Shiang-Li Chen
Director24.6yrsNT$306.90kno data
Chia-Chun Chen
Independent Director11.1yrsNT$778.50kno data
Wei-Chyun Wong
Chairman24.6yrsNT$7.00m0.62%
NT$ 33.1m
Lan-Ching Chang
Independent Director1.2yrsno datano data
Chin-Hsin Hsu
Representative Director2.2yrsno datano data
Vincent Wang
Independent Director4.1yrsNT$732.00k0.045%
NT$ 2.4m
11.1yrs
Average Tenure

Experienced Board: 4119's board of directors are seasoned and experienced ( 11.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 23:19
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SCI Pharmtech, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yu-Ying YangKGI Securities Co. Ltd.
Xiaowei HuangMasterlink Securities Investment Advisory
Yijun ChenSinoPac Securities Investment Service